Lebrikizumab Provides Rapid Clinical Responses Across All Eczema Area and Severity Index Body Regions and Clinical Signs in Adolescents and Adults with Moderate-to-Severe Atopic Dermatitis

• Váldodahkkit: Eric L. Simpson (Dahkki), Marjolein de Bruin-Weller (Dahkki), H. Chih-ho Hong (Dahkki), Delphine Staumont-Sallé (Dahkki), Andrew Blauvelt (Dahkki), Kilian Eyerich (Dahkki), Melinda Gooderham (Dahkki), Mona Shahriari (Dahkki), Lotus Mallbris (Dahkki), Amber Reck Atwater (Dahkki), Maria Jose Rueda (Dahkki), Yuxin Ding (Dahkki), Zhuqing Liu (Dahkki), Helena Agell (Dahkki), Jonathan I. Silverberg (Dahkki)
• Materiálatiipa: Girji
• Almmustuhtton: Adis, Springer Healthcare, 2024-05-01T00:00:00Z.
• Fáttát: article
• Liŋkkat: Connect to this object online.

Abstract Introduction Atopic dermatitis (AD) affects multiple areas of the body, some of which may be more refractory to treatment. We evaluated improvements in the Eczema Area and Severity Index (EASI) by body region and clinical signs for each body region in lebrikizumab-treated patients with mode...